Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide

George W. Santos, Peter J. Tutschka, Ronald Brookmeyer, Rein Saral, William E. Beschorner, Wilma B. Bias, Hayden G. Braine, William H. Burns, Gerald J. Elfenbein, Herbert Kaizer, David Mellits, Lyle L. Sensenbrenner, Robert K. Stuart, Andrew M. Yeager

Research output: Contribution to journalArticlepeer-review

715 Scopus citations


Fifty-one patients with acute nonlymphocytic leukemia (16 with end-stage disease, 17 in second or third remission or in early relapse, and 18 in first remission) were given infusions of HLA-identical sibling marrow after cytoreduction with high doses of busulfan and cyclophosphamide. Actuarial two-year survival rates were 0 per cent, 29 per cent, and 44 per cent, respectively. Twelve patients are still alive and in remission after 327 to 1488 days, with 10 surviving beyond two years. Acute graft-versus-host disease and viral pneumonia were the major causes of death. Leukemic cells failed to clear in one patient with end-stage disease, and a relapse with meningeal leukemia occurred in another. Only one other relapse was seen — in a patient given a transplant during a third remission. Survival was favorably affected by younger age and transplantation during first remission. We conclude that high-dose chemotherapy with busulfan and cyclophosphamide, followed by allogeneic-marrow transplantation, can produce long-term remission of acute leukemia. Chemotherapy with high-dose busulfan and cyclophosphamide before transplantation provides an effective alternative to cyclophosphamide and total-body irradiation before transplantation for the treatment of acute nonlymphocytic leukemia. (N Engl J Med 1983: 309:1347–53.).

Original languageEnglish (US)
Pages (from-to)1347-1353
Number of pages7
JournalNew England Journal of Medicine
Issue number22
StatePublished - Dec 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and Cyclophosphamide'. Together they form a unique fingerprint.

Cite this